RichardAnthonyWalgrenMDPhD

PubMed

• 2 citations
  RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
  Kazuhiko Nakagawa, Edward B Garon, Ling Gao, Sophie Callies, Annamaria Zimmermann, Richard Walgren, Carla Visseren-Grul, Martin Reck> ;Cancer Chemotherapy and Pharmacology. 2022 Aug 1
• 22 citations
  Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicen...
  Juan W. Valle, Arndt Vogel, Crystal S. Denlinger, Aiwu Ruth He, Li Yuan Bai, Rashida Orlova, Eric Van Cutsem, Jorge Adeva, Li-Tzong Chen, Radka Obermannova, Thomas J. ...> ;The Lancet. Oncology. 2021 Oct 1
• 3 citations
  Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
  Hiroya Taniguchi, Takayuki Yoshino, Kensei Yamaguchi, Kentaro Yamazaki, Andrew B. Nixon, Josep Tabernero, Eric Van Cutsem, Kim R Robling, Paolo Abada, Rebecca R. Hozak...> ;Current Medical Research and Opinion. 2021 Jul 28
• 48 citations
  Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): ove...
  Daniel P. Petrylak, Ronald de Wit, Kim N. Chi, Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aude Flechon, Aristotelis ...> ;The Lancet. Oncology. 2020 Jan 1
• 32 citations
  First‐in‐Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
  Aiwu Ruth He, Roger B. Cohen, Crystal S. Denlinger, Ashwin Reddy Sama, Ariel E. Birnbaum, Jimmy J. Hwang, Takami Sato, Nancy Lewis, Michelle Mynderse, Michele Niland, ...> ;The Oncologist. 2019 Sep 1
• 23 citations
  MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
  S. Betty Yan, Suzane L. Um, Victoria L. Peek, Jennifer R. Stephens, Wei Zeng, Bruce W. Konicek, Ling Liu, Jason Manro, Volker Wacheck, Richard A. Walgren> ;Investigational New Drugs. 2018 Aug 1
• 37 citations
  Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms
  Jesus G. Berdeja, Francesca Palandri, Maria R. Baer, Donald P. Quick, Jean-Jacques Kiladjian, Giovanni Martinelli, Amit Verma, O Hamid, Richard A. Walgren, Celine Pito...> ;Leukemia Research. 2018 Aug 1
• 66 citations
  LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial.
  Talia Golan, Ravit Geva, Donald A. Richards, Srinivasan Madhusudan, Boris Lin, Haofei Tiffany Wang, Richard A. Walgren, Salomon M. Stemmer> ;Journal of Cachexia, Sarcopenia and Muscle. 2018 Jul 27
• 110 citations
  Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).
  Hendrik-Tobias Arkenau, Juan Martin-Liberal, Emiliano Calvo, Nicolas Penel, Matthew G Krebs, Roy S. Herbst, Richard A. Walgren, Ryan C. Widau, Gu Mi, Jin Jin, David Fe...> ;The Oncologist. 2018 Dec 1
• 33 citations
  Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
  Bruce W. Konicek, Andrew Capen, Kelly M. Credille, Philip J. Ebert, Beverly L. Falcon, Gary L. Heady, Bharvin K. R. Patel, Victoria L. Peek, Jennifer R. Stephens, Juli...> ;Oncotarget. 2018 Feb 13
• 27 citations
  A phase 1 study of the Janus kinase 2 (JAK2) V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thromboc...
  Srdan Verstovsek, Ruben A. Mesa, Mohamed E. Salama, Li Li, Celine Pitou, Fabio P. Nunes, Gregory L Price, Jennifer L K Giles, Deborah N. D'Souza, Richard A. Walgren, J...> ;Leukemia Research. 2017 Oct 1
• 57 citations
  Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Thr...
  Daniel P. Petrylak, Scott T. Tagawa, Manish Kohli, Andrea Eisen, Christina Canil, Srikala S. Sridhar, Alexander I. Spira, Evan Y. Yu, John M. Burke, David R. Shaffer, ...> ;Journal of Clinical Oncology. 2016 Sep 27
• 47 citations
  Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
  Gregory L Price, Keith L. Davis, Sudeep Karve, Gerhardt Pohl, Richard A. Walgren> ;Plos One. 2014 Mar 11
• 47 citations
  Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
  Wenjuan Wu, Chen Bi, Kelly M. Credille, Jason Manro, Victoria L. Peek, Gregory P. Donoho, Lei Yan, John A. Wijsman, S. Betty Yan, Richard A. Walgren> ;Clinical Cancer Research. 2013 Oct 15
• 113 citations
  LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse...
  S. Betty Yan, Victoria L. Peek, Rose T. Ajamie, Sean Buchanan, Jeremy R. Graff, Steven A. Heidler, Yu-Hua Hui, Karen L. Huss, Bruce W. Konicek, Jason Manro, Chuan Shih...> ;Investigational New Drugs. 2013 Aug 1
• 45 citations
  Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F.
  Liandong Ma, Joshua Ryan Clayton, Richard A. Walgren, Baohui Zhao, R J Evans, Michele C. Smith, K M Heinz-Taheny, Emiko L. Kreklau, Laura J. Bloem, Celine Pitou, W She...> ;Blood Cancer Journal. 2013 Apr 12
• 35 citations
  A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.
  Michael G. Martin, Richard A. Walgren, Elizabeth Procknow, Geoffrey L. Uy, Keith Stockerl-Goldstein, Amanda F. Cashen, Peter Westervelt, Camille N. Abboud, Frederieke ...> ;American Journal of Hematology. 2009 Sep 1
• 71 citations
  Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.
  Jeffrey Knight, Andrew D. Skol, Abhijit Shinde, Darcie Hastings, Richard A. Walgren, Jin Shao, Thelma R. Tennant, Mekhala Banerjee, James M. Allan, Michelle M. Le Beau...> ;Blood. 2009 May 28
• 40 citations
  Integrated Genomic Analysis Implicates Haploinsufficiency of Multiple Chromosome 5q31.2 Genes in De Novo Myelodysplastic Syndromes Pathogenesis
  Timothy A. Graubert, Michelle A. Payton, Jin Shao, Richard A. Walgren, Ryan Monahan, John L. Frater, Mark A. Walshauser, Michael G. Martin, Yumi Kasai, Matthew J. Walter> ;Plos One. 2009 Feb 25
• A phase II study of intravenous azacitidine alone in patients with myelodysplastic syndromes: NCT0038495.
  Walgren RA, Dao C, Kreisel F, Westervelt P, Abboud CN, Graubert T, Cashen AF, Uy GL, Gao F, Dipersio JF, Vij R> ;J. Clin. Oncol.. 2008-05-20
• 186 citations
  Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
  Michael H. Tomasson, Zhifu Xiang, Richard A. Walgren, Yu Zhao, Yumi Kasai, Tracie L. Miner, Rhonda E. Ries, Olga Y. Lubman, Daved H. Fremont, Michael D. McLellan, Jacq...> ;Blood. 2008 May 1
• 21 citations
  Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?
  Richard A. Walgren, Melissa A. Meucci, Howard L. McLeod> ;Journal of Clinical Oncology. 2005 Oct 10
• 1 citations
  Small inhibitory RNA – a tool for credentialing candidate genes
  Richard A. Walgren, Howard L. McLeod> ;Pharmacogenomics. 2005 Nov 24
• 2 citations
  Autoradiographic localization of [125I-Tyr0]bradykinin binding sites in brains of Wistar-Kyoto and spontaneously hypertensive rats.
  Philip J. Privitera, Robert M. Beckstead, Phillip W. Yates, Richard A. Walgren> ;Cellular and Molecular Neurobiology. 2003 Oct 1
• 190 citations
  Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1.
  Richard A. Walgren, Jiann-Trzuo Lin, Rolf K. H. Kinne, Thomas Walle> ;The Journal of Pharmacology and Experimental Therapeutics. 2000 Sep 1
• Join now to see all